Synbionik is the first European biotech company fully dedicated to the application of synthetic biology to the production of biochemicals from microorganisms.
Our differentiating strategy is to work in modular, proprietary and patent-protectable ways across every dimension (microorganisms, bioreactors, downstreaming processes). This platform allows for drastic cost, purity and sustainability advantages over traditional production methods.
For cannabinoids (e.g. CBD), we expect to achieve productivity advantages of 10x – 100x or more over the targets of the most promising biosynthetic methods currently in development. Beyond cannabinoids, Synbionik develops end-to-end production platforms for other high-value biochemicals, with similar productivity and cost advantages (10x-100x).